Galmed identifies proprietary biomarker signature for aramchol, unlocking multi-billion-dollar expansion potential beyond nash

Biomarker analysis from phase 3 armor study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. validated decrease in anp (atrial natriuretic peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.
GLMD Ratings Summary
GLMD Quant Ranking